Mark Benton

Title: Mark Benton: Innovator in Allogeneic Cell Therapy

Introduction

Mark Benton is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cell therapy, particularly in the treatment of B cell malignancies. His innovative approach utilizes genetically engineered T cells to target specific cancer cells, showcasing the potential of advanced immunotherapy.

Latest Patents

Mark Benton holds a patent for "Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19." This patent describes a population of genetically engineered immune cells, specifically T cells, that express a chimeric antigen receptor (CAR) targeting CD19. The cells also contain a disrupted TRAC gene, a disrupted B2M gene, or both, which enhances their effectiveness in treating B cell malignancies.

Career Highlights

Mark Benton is currently associated with Crispr Therapeutics AG, a company at the forefront of gene editing and cell therapy innovations. His work focuses on developing cutting-edge therapies that leverage the power of CRISPR technology to improve patient outcomes in oncology.

Collaborations

Mark collaborates with notable colleagues, including Tony Ho and Demetrios Kalaitzidis. Their combined expertise contributes to the advancement of research and development in the field of immunotherapy.

Conclusion

Mark Benton is a key figure in the realm of allogeneic cell therapy, with a focus on innovative treatments for B cell malignancies. His contributions and collaborations continue to push the boundaries of medical science, offering hope for improved cancer therapies.